Clean Science and Technology Limited — Investor Meet, 04-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Clean Science reported Q3 FY26 consolidated revenue of INR 216 Cr (down 10% QoQ) and PAT of INR 46 Cr (21% margin). Standalone revenue was INR 180 Cr (PAT 29% margin). Volumes for MEHQ/BHA and FMCG (4-MAP) faced pricing pressure and US tariffs. Positively, the HALS business showed strong 55% YoY growth and achieved EBITDA breakeven.

Management highlighted challenging market conditions with muted demand and China's overcapacity. They are focused on operational efficiency and new product development. Hydroquinone and catechol plants are operational, enhancing downstream margins. Performance Chemical 2 is expected in Q1 FY27. Despite a cautious short-term outlook, the company maintains strong cash (INR 450 Cr) and a long-term focus, approving an interim dividend of INR 2/share.